Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
CHF 0
Key Takeaways
Risk factor
Significant default risk
Profitability factor
Strong growth
Data is available to registered users only
Data is available to registered users only
About
Perfect Holding SA, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics for the treatment of viral, respiratory, and ophthalmic diseases. Its therapeutic drug candidate is KIN001, an advanced clinical stage p38 MAPK inhibitor combined with a marketed drug together enabling an oral long-term treatment for patients suffering from diseases. The company is based in Lausanne, Switzerland.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EB
Data is available to registered users only
Buy
Sell